-
Columbia Laboratories Added to Russell 3000 Index
Friday, June 24, 2011 - 4:31pm | 118Columbia Laboratories (Nasdaq: CBRX) today announced that it was added to the Russell 3000® Index effective following the market close on Friday, June 24, 2011. The Russell 3000 serves as the U.S. component to the Russell Global Index. "We believe our inclusion in the Russell indexes will provide...
-
Piper Jaffray Reiterates Overweight, $23 PT
Friday, June 24, 2011 - 12:34pm | 123Piper Jaffray reiterated its ViroPharma (NASDAQ: VPHM) Overweight rating and $23 price target in a research report published today. In the report, Piper Jaffray states, "While this is a niche market with an estimated $50 million in peak sales, we believe Buccolam will leverage ViroPharma's existing...
-
Abbott Laboratories Announces New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function
Friday, June 24, 2011 - 10:17am | 143Abbott Laboratories (NYSE: ABT) New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney...
-
European Authorities Approve New Manufacturing Facility for Shire's REPLAGAL
Friday, June 24, 2011 - 9:55am | 114Shire plc (NASDAQ: SHPGY) today announced that the European Medicines Agency has approved the purification of REPLAGAL drug substance at its new manufacturing facility in Lexington, MA, US. REPLAGAL, Shire's enzyme replacement therapy for the treatment of Fabry disease is the first product that...
-
Lannett Receives FDA Approval for Morphine Sulfate Oral Solution NDA
Friday, June 24, 2011 - 9:35am | 68Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration has approved the company's 505(b)(2) New Drug Application for Morphine Sulfate Oral Solution on June 23, 2011. Sales of Morphine Sulfate Oral Solution for the last 12 months at Average Wholesale prices...
-
Pain Therapeutics Tradong Over 45% Lower After FDA Rejection
Friday, June 24, 2011 - 9:34am | 68Pfizer (NYSE: PFE) and Pain Therapeutics, Inc. (NASDAQ: PTIE) announced that a Complete Response Letter was received from the U.S. Food and Drug Administration on the resubmission to the new drug application for REMOXY Extended-Release Capsules CII. Read more here.
-
Morgan Stanley Reiterates Equal-Weight on Merck
Friday, June 24, 2011 - 9:20am | 52Morgan Stanley reiterated its Equal-weight rating on Merck (NYSE: MRK). At the moment, Morgan Stanley has a price target of $34 placed on the company's stock. On Thursday, Merck ended the day $34.97. Its shares added 0.49% to their value in today's pre-market trading to stand around $35.14.
-
Lannett Confirms that a Press Release About its Morphine Sulfate Oral Solution FDA Response will be Released Today
Friday, June 24, 2011 - 9:13am | 97Lannett (NYSE: LCI) will release a FDA response to its morphine sulfate oral solution and other drug applications later today via a press release, as confirmed by a call by Benzinga to the company. Note: Lannett originally had a PDUFA date scheduled for yesterday, June 23, 2011. That revised PDUFA...
-
Morgan Stanley Reiterates Overweight and PT of $22 on Pfizer
Friday, June 24, 2011 - 9:13am | 54Morgan Stanley reiterated its Overweight rating on Pfizer (NYSE: PFE). At the same time, the rating agency decided to leave its price target on the company's stock unchanged at $22. On Thursday, Pfizer ended the day at $20.65. Its shares lost 0.44% in today's pre-market trading to trade around $20....
-
Eli Lilly: Linagliptin Recommended For Approval In The Treatment Of Type 2 Diabetes In Europe
Friday, June 24, 2011 - 8:56am | 351Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today received a positive opinion from the European Medicines Agency's (EMA) medicinal committee recommending approval of linagliptin, 5 mg, film-coated tablets (to be marketed under the trade name Trajenta® in Europe) for the treatment of...
-
Benzinga's Top Pre-Market NASDAQ Losers
Friday, June 24, 2011 - 8:26am | 131Pain Therapeutics (NASDAQ: PTIE) dipped 32.25% to $6.26 in the pre-market session. Pfizer (NYSE: PFE) and PTIE received a Complete Response Letter from the US Food and Drug Administration (FDA) on the resubmission to the new drug application (NDA) for REMOXY. Durect Corporation (NASDAQ: DRRX)...
-
J.P. Morgan Maintains Overweight Rating On Mylan
Friday, June 24, 2011 - 8:25am | 88According to J.P. Morgan, Mylan (NYSE: MYL) launch of a generic version of Entocort EC (budesonide capsules, $330mm in 2010 IMS reported sales) is an incremental positive for the stock. J.P. Morgan said that, with only one other known filer on the product, generic Entocort EC represents an...
-
Deutsche Bank Updates 6/24
Friday, June 24, 2011 - 8:10am | 504Deutsche Bank made a number of updates in a research report published today. NASDAQ OMX (NASDAQ: NDAQ) had its rating reiterated at Hold. At the same time, however, its price target was lowered from $30 to $27. On Thursday, NASDAQ lost 2.59% of its value to close the day at $23.35. CBOE Holdings...
-
Pfizer and Pain Therapeutics Announce FDA Complete Response Letter Received for REMOXY
Friday, June 24, 2011 - 8:01am | 77Pfizer (NYSE: PFE) and Pain Therapeutics, Inc. (NASDAQ: PTIE) announced that a Complete Response Letter was received from the U.S. Food and Drug Administration on the resubmission to the new drug application for REMOXY Extended-Release Capsules CII. Pfizer is working to evaluate the issues...
-
Pain Therapeutics Down 42% Pre-Market on FDA Rejection
Friday, June 24, 2011 - 7:54am | 42Pain Therapeutics (NASDAQ: PTIE) is down 42% pre-market on the reports that FDA rejected company's new painkiller. The stock is currently halted on pending news. Pain Therapeutics was trading at $5.35 pre-market before the trading halt..